Navneet Agrawal
Diabetes, Obesity and Thyroid Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Navneet Agrawal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:34 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT00814372 · Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on MetforminGilead Sciences · terminated · Type 2 Diabetes Mellitus · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:34 UTC. The ranking covers the 200 most relevant of 106 PubMed records, and a shared surname and initials can bring in a namesake. All 106 on PubMed
- 2,428 citationsRCR 71.5
- Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial.Lancet · 1988634 citationsRCR 33.5
- 409 citationsRCR 16.7
- 375 citationsRCR 22.7
- Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.Am J Med · 2006246 citationsRCR 7.6
- Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.Arch Intern Med · 2002232 citationsRCR 7.3
- Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial.Ann Intern Med · 1991175 citationsRCR 8.7
- OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.Ann Oncol · 2019169 citationsRCR 7.8
- Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.Clin Cancer Res · 2015163 citationsRCR 4.8
- New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.Clin Infect Dis · 2008154 citationsRCR 5.6